natgillin/translations-raw huggingface dataset:
- if you have ever been diagnosed with a condition whose symptoms include high temperature and muscle stiffness (also known as Neuroleptic Malignant Syndrome).
- Če so vam kdaj diagnosticirali stanje s simptomi kot sta visoka telesna temperatura in mišična okorelost (znano tudi kot nevroleptični maligni sindrom) ali - če ste kdaj občutili nenormalne gibe jezika ali obraza (tardivno diskinezijo)
• a change in the way you walk
• sprememba načina hoje
The INVEGA group in the flexible-dose study (dosed between 3 and 12 mg/day, mean modal dose of 8.6 mg/day) and the higher dose group of INVEGA in the 2 dose-level study (12 mg/day with option to reduce to 9 mg/day) were each superior to placebo in the PANSS at 6 weeks.
Skupina, v kateri so preiskovanci prejemali zdravilo INVEGA v študiji s prilagodljivim odmerkom (odmerek od 3 do 12 mg/dan, povprečni modalni odmerek 8,6 mg/dan), in skupina, v kateri so preiskovanci prejemali večji odmerek zdravila INVEGA v študiji z dvema ravnema odmerkov (12 mg/dan z možnostjo zmanjšanja na 9 mg/dan), sta bili uspešnejši pri rezultatu PANSS od skupine, v kateri so preiskovanci prejemali placebo.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Če imate dodatna vprašanja o uporabi tega zdravila, se posvetujte z zdravnikom, s farmacevtom ali medicinsko sestro.
Bottles: Do not store above 30°C.
Vsebniki: Shranjujte pri temperaturi do 30 C.
Co-administration of INVEGA 12 mg once daily with divalproex sodium prolonged-release tablets (500 mg to 2,000 mg once daily) did not affect the steady-state pharmacokinetics of valproate.
Sočasna uporaba 12 mg zdravila INVEGA enkrat na dan in tablet natrijevega valproata/valprojske kisline (divalproeks) s podaljšanim sproščanjem (od 500 mg do 2000 mg enkrat na dan) ni vplivala na farmakokinetiko valproata v stanju dinamičnega ravnovesja.
• infection of the chest (bronchitis), common cold symptoms, sinus infection, urinary tract infection, feeling like you have the flu
• okužba dihal (bronhitis), simptomi prehlada, okužba sinusov, okužba sečil, občutek, da imate gripo
These tumours can be related to prolonged dopamine D2 antagonism and hyperprolactinemia.
Ti tumorji so lahko povezani z dolgotrajnejšim antagonističnim delovanjem na dopaminske receptorje D2 in s hiperprolaktinemijo.
In the schizoaffective disorder studies, the incidence of EPS was observed at a higher rate than placebo in all dose groups without a clear relationship to dose.
V študijah shizoafektivne motnje je bila incidenca ekstrapiramidnih simptomov pri vseh skupinah, ki so prejemale odmerek zdravila, večja kot pri placebu, brez jasne povezave z odmerkom.
• experience a severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash and sometimes drop in blood pressure (amounting to an ‘anaphylactic reaction').
• imate resne alergijske reakcije za katere so značilni vročina, otekla ustna sluznica, obraz, ustnice ali jezik, težko dihanje, srbenje, kožni izpuščaji in včasih tudi znižanje krvnega tlaka (ki so posledica anafilaktične reakcije).
• fever, weakness, fatigue (tiredness).
• vročina, šibkost, utrujenost
LOCF endpoint change from baseline
LOCF sprememba od izhodiščne vrednosti.
INVEGA is indicated for the treatment of schizoaffective disorder in adults.
Zdravilo INVEGA je indicirano za zdravljenje shizoafektivne motnje pri odraslih.
Adverse reactions that may suggest increase in prolactin levels (e.g., amenorrhoea, galactorrhoea, menstrual disturbances, gynaecomastia) were reported overall in 2% of subjects.
O neželenih učinkih, ki bi lahko bili povezani s prolaktinom (npr. o amenoreji, galaktoreji, menstrualnih motnjah, ginekomastiji) pa so poročali pri skupaj 2% preiskovancev.
It must not be chewed, broken, or crushed.
Tablet ne smete žvečiti, razdeliti ali drobiti.
• eye infection, fungal infection of the nails, infection of the skin, skin inflammation caused by mites
• okužba oči, glivična okužba nohtov,okužba kože, vnetje kože povzročeno s pršicami
Adolescents weighing ≥ 51 kg: the maximum recommended daily dose of INVEGA is 12 mg.
Mladostniki s telesno maso ≥ 51 kg: največji priporočeni dnevni odmerek zdravila INVEGA je 12 mg.
Larger decreases in plasma concentrations of paliperidone could occur with higher doses of carbamazepine.
Pri višjih odmerkih karbamazepina se lahko pojavi večje znižanje plazemskih koncentracij paliperidona.
• an increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown, muscle spasms, joint stiffness, joint swelling, muscle weakness, neck pain
• zvišana koncentracija CPK (kreatin fosfokinaze) v krvi; encima, ki se včasih sprosti ob razpadanju mišic, mišičnih krčih, okorelosti sklepov, otekanju sklepov, šibkosti mišic, bolečini v vratu
Venous thromboembolism
Venski trombemolizem
Pack sizes of 14, 28, 30, 49, 56, and 98 prolonged-release tablets.
Velikosti pakiranj: 14, 28, 30, 49, 56 in 98 tablet s podaljšanim sproščanjem.
No data are available in patients with a creatinine clearance below 10 mL/min.
Za bolnike z očistkom kreatinina, manjšim od 10 ml/min ni podatkov.
The 3 mg tablets are white and printed with “PAL 3”, the 6 mg tablets are beige and printed with “PAL 6”, the 9 mg tablets are pink and printed with “PAL 9”, and the 12 mg tablets are dark yellow and printed with “PAL 12”.
3 mg tablete so bele z oznako “PAL 3”, 6 mg tablete so rjavkaste z oznako “PAL 6”, 9 mg tablete so roza z oznako “PAL 9” in 12 mg tablete so temno rumene z oznako “PAL 12”.
The patient should be instructed to always take INVEGA in the fasting state or always take it together with breakfast and not to alternate between administration in the fasting state or in the fed state.
Bolniku naročite, naj zdravilo INVEGA jemlje bodisi vedno na tešče ali pa vedno z zajtrkom in naj ne spreminja načina jemanja, to je naj zdravila ne jemlje enkrat na tešče in enkrat z zajtrkom.
In the lower dose group of the 2 dose-level study (6 mg/day with option to reduce to 3 mg/day), INVEGA was not significantly different from placebo as measured by the PANSS.
V študiji z dvema ravnema odmerkov, v skupini, v kateri so preiskovanci prejemali manjši odmerek (6 mg/dan z možnostjo zmanjšanja na 3 mg/dan), se zdravilo INVEGA ni bistveno razlikovalo od placeba pri rezultatu vprašalnika PANSS.
Each bottle contains two 1 g dessicant silica gel (silicone dioxide) pouches (pouch is food approved polyethylene).
En vsebnik vsebuje dve vrečki (iz polietilena, odobrenega za uporabo pri pakiranju živil) z 1 g sušilnega sredstva iz silikagela (silicijevega dioksida).
Pack sizes of 14, 28, 49, 56, and 98 prolonged-release tablets.
Velikosti pakiranj: 14, 28, 49, 56 in 98 tablet s podaljšanim sproščanjem.
QT prolongation, ventricular arrythmias (ventricular fibrillation, ventricular tachycardia), sudden unexplained death, cardiac arrest and Torsade de pointes may occur with antipsychotics.
Pri uporabi antipsihotikov, lahko pride do podaljšanja QT intervala, ventrikularnih aritmij (ventrikularna fibrilacija, ventrikularna tahikardija), nenadne nepričakovane smrti, srčnega zastoja in Torsade de pointes.
White high-density polyethylene (HDPE) bottle with induction sealing and polypropylene child-resistant closure.
Beli vsebniki iz polietilena velike gostote (HDPE) z indukcijsko zaporo in polipropilensko zaporko, varno za otroke.
Neuroleptic Malignant Syndrome (NMS), characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness, and elevated serum creatine phosphokinase levels has been reported to occur with paliperidone.
Poročali so, da se pri uporabi paliperidona lahko pojavi nevroleptični maligni sindrom (NMS), za katerega so značilni hipertermija, mišična rigidnost, avtonomna nestabilnost, spremenjeno stanje zavesti in zvišana serumska koncentracija kreatin fosfokinaze.
Posology
VSEBNIK
• a blockage in the bowels, stool incontinence, very hard stool, lack of bowel muscle movement that causes blockage
• zaprtje črevesja, nezmožnost zadrževanja blata, zelo trdo blato, zmanjšano gibanje črevesa, ki povzroči zastoj
Caution is advised if paliperidone is combined with other medicines known to lower the seizure threshold (i.e., phenothiazines or butyrophenones, clozapine, tricyclics or SSRIs, tramadol, mefloquine, etc.).
Če se paliperidon uporablja sočasno z zdravili, ki znižajo prag za krče oz. epileptične napade (npr. fenotiazini ali butirofenoni, klozapin, triciklični antidepresivi ali SSRI, tramadol meflokin itd.) je potrebna previdnost.
Hypromellose Titanium dioxide (E171) Lactose monohydrate Triacetin
Obloga hipromeloza titanov dioksid (E171) laktoza monohidrat triacetin karnauba vosek
With once-daily dosing of INVEGA, steady-state concentrations of paliperidone are attained within 4-5 days of dosing in most subjects.
Pri odmerjanju zdravila INVEGA enkrat na dan je bila pri večini preiskovancev koncentracija paliperidona v stanju dinamičnega ravnovesja dosežena v 4 do 5 dneh jemanja zdravila.
Some patients may benefit from lower or higher doses within the recommended range of 3 mg to 12 mg once daily.
Nekaterim bolnikom lahko pomagajo tudi manjši ali večji odmerki, v razponu priporočenih odmerkov od 3 mg do 12 mg enkrat na dan.
Undesirable effects noted with risperidone formulations Paliperidone is the active metabolite of risperidone, therefore, the adverse reaction profiles of these compounds (including both the oral and injectable formulations) are relevant to one another.
Neželeni učinki poročani z različnimi oblikami risperidona Paliperidon je aktivni presnovek risperidona, zato sta njuna profila neželenih učinkov (peroralne oblike in injekcije) odvisna eden od drugega.
Concomitant use of INVEGA with oral risperidone is not recommended as paliperidone is the active metabolite of risperidone and the combination of the two may lead to additive paliperidone exposure.
Sočasna uporaba zdravila INVEGA in risperidona Sočasne uporabe zdravila INVEGA s peroralnim risperidonom ni priporočljiva, ker je paliperidon aktivni presnovek risperidona, zato lahko pri sočasni uporabi obeh pride do aditivne izpostavljenosti paliperidonu.
EPS included a pooled analysis of the following terms: Parkinsonism (includes salivary hypersecretion, musculoskeletal stiffness, parkinsonism, drooling, cogwheel rigidity, bradykinesia, hypokinesia, masked facies, muscle tightness, akinesia, nuchal rigidity, muscle rigidity, parkinsonian gait, and glabellar reflex abnormal, parkinsonian rest tremor), akathisia (includes akathisia, restlessness, hyperkinesia, and restless leg syndrome), dyskinesia (dyskinesia, muscle twitching, choreoathetosis, athetosis, and myoclonus), dystonia (includes dystonia, hypertonia, torticollis, muscle contractions involuntary, muscle contracture, blepharospasm, oculogyration, tongue paralysis, facial spasm, laryngospasm, myotonia, opisthotonus, oropharyngeal spasm, pleurothotonus, tongue spasm, and trismus), and tremor.
Pri EPS so opravili tudi analizo zbranih podatkov za naslednje izraze: parkinsonizem (vključuje hipersekrecijo sline, otrdelost mišic, parkinsonizem, slinjenje, rigidnost tipa zobatega kolesa, bradikinezijo, hipokinezijo, obraz kot maska, napetost mišic, akinezijo, rigidnost vratu, rigidnost mišic, parkinsonsko držo, nenormalni glaberalni refleks), parkinsonski tremor v mirovanju; akatizija (vključuje akatizijo, nemir, hiperkinezijo in sindrom nemirnih nog); diskinezija (diskinezija, trzanje mišic, horeoatetoza, atetoza in mioklonus); distonija (vključuje distonijo, hipertonijo, tortikolis, nenadzorovano krčenje mišic, krčenje mišic, blefarospazem, okulogiracijo, paralizo jezika, obrazne krče, laringospazem, miotonijo, opistotonus, orofaringealne krče, plevrototonus, krče jezika in trizmus) in tremor.
Because of its potential for inducing orthostatic hypotension (see section 4.4), an additive effect may be observed when INVEGA is administered with other therapeutic agents that have this potential, e.g., other antipsychotics, tricyclics.
Ker to zdravilo lahko povzroči ortostatsko hipotenzijo (glejte poglavje 4.4), pri sočasni uporabi zdravila INVEGA in drugih zdravil z enakim delovanjem npr.: drugi antipsihotiki, triciklični antidepresivi lahko opazimo aditivni učinek.
Some patients may benefit from higher doses within the recommended range of 6 mg to 12 mg once daily.
Nekaterim bolnikom lahko pomagajo tudi večji odmerki, v razponu priporočenih odmerkov od 6 mg do 12 mg enkrat na dan.
Response defined as decrease from baseline in PANSS Total Score ≥ 30% and CGI-C Score ≤ 2
Odziv je opredeljen kot zmanjšanje celotnega rezultata PANSS za ≥ 30 % in rezultata CGI-C za ≤ 2 od izhodiščne vrednosti.
In schizoaffective disorder clinical trials, a higher percentage of INVEGA-treated subjects (5%) had an increase in body weight of ≥ 7% compared with placebo-treated subjects (1%).
V kliničnih preskušanjih shizoafektivne motnje je bilo povečanje telesne mase za ≥ 7% večje pri preiskovancih, ki so prejemali zdravilo INVEGA (5%), kot pri preiskovancih, ki so prejemali placebo (1%).
3 mg tablets Contains lactose.
3 mg tablete Vsebujejo laktozo.
The efficacy of INVEGA in the treatment of schizophrenia in adolescents between 12 and 14 years old has not been established.
Učinkovitosti zdravila INVEGA pri zdravljenju shizofrenije pri mladostnikih, starih med 12 in 14 let, niso dokazali.
Response defined as decrease from baseline in PANSS Total Score ≥ 20% Note: Negative change in score indicates improvement.
Odgovor je opredeljen kot zmanjšanje skupnega rezultata PANSS za ≥ 20% od izhodiščne vrednosti.
Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leucopenia/neutropenia should be monitored during the first few months of therapy and discontinuation of INVEGA should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.
Bolnike, ki so že imeli klinično pomembno majhno število levkocitov (WBC) ali z zdravilom izzvano levkopenijo/nevtropenijo je treba skrbno spremljati prve mesece zdravljenja.
• low blood pressure upon standing (consequently, some people taking INVEGA may feel faint,
• nizek krvni tlak ob vstajanju (nekateri bolniki, ki jemljejo zdravilo INVEGA, so posledično lahko posledično omotični, omedlijo ali izgubijo zavest, ko vstanejo ali se nanadoma vsedejo),
The recommended starting dose for treating schizophrenia in adolescents 15 years and older is 3 mg once a day taken in the morning.
Priporočeni začetni odmerek za zdravljenje shizofrenije pri mladostnikih, starih 15 let in več je 3 mg enkrat na dan zjutraj.
However, there was no discernable effect of age in the population pharmacokinetic analysis involving schizophrenia subjects after correction of age-related decreases in CrCl.
V analizi populacijske farmakokinetike pri preiskovancih s shizofrenijo pa ni bilo vidnega vpliva starosti po korekciji za starostno zmanjšanje očistka kreatinina.
Metabolism and nutrition disorders weight increased, increased appetite, weight decreased, decreased appetite diabetes mellitus d,
Presnovne in prehranske motnje zvečana telesna masa, povečan tek, zmanjšana telesna masa, zmanjšan apetit sladkorna bolezen d,
Paliperidone should be used with caution in patients with possible prolactin-dependent tumours.
Pri bolnikih z morebitnimi, od prolaktina odvisnimi tumorji je treba paliperidon uporabljati previdno.
Adolescents weighing < 51 kg: the maximum recommended daily dose of INVEGA is 6 mg.
Mladostniki s telesno maso < 51 kg: največji priporočeni dnevni odmerek zdravila INVEGA je 6 mg.
After having been successfully treated for an acute psychotic or mood episode for 13 weeks and stabilised for an additional 12 weeks with the long-acting injectable formulation of paliperidone (doses ranging from 50 to 150 mg) patients were then randomised to a 15-month double-blind relapse prevention period of the study to either continue on the long-acting injectable formulation of paliperidone or on placebo until they experienced a relapse of schizoaffective symptoms.
Po uspešnem 13-tedenskem zdravljenju akutne psihotične epizode in nihanja razpoloženja ter stabilizacij stanja z injekcijami paliperidona s podaljšanim sproščanjem dodatnih 12 tednov (odmerki so bili v razponu od 50 do 150 mg), so bolnike randomizirali v 15-mesečno dvojno slepo obdobje preprečevanja relapsov v dve skupini.
Blood and lymphatic system disorders white blood cell count decreased, thrombocytopenia, anaemia, haematocrit decreased agranulocytosis c,
Bolezni krvi in limfatičnega sistema levkopenija, trombocitopenija, anemija, zmanjšan hematokrit agranulocitoza c,
Vascular disorders orthostatic hypotension, hypertension hypotension pulmonary embolism, venous thrombosis,
Žilne bolezni ortostatska hipotenzija, hipertenzija hipotenzija pljučna embolija, venska tromboza, ishemija, rdečica
Not observed in INVEGA clinical studies but observed in post-marketing environment with paliperidone In placebo-controlled pivotal trials, diabetes mellitus was reported in 0.05% in INVEGA-treated subjects compared to a rate of 0% in placebo group.
V s placebom nadzorovanih ključnih preskušanjih so pri bolnikih, zdravljenih z zdravilom INVEGA, poročali o sladkorni bolezni pri 0,05% bolnikov v primerjavi z 0% bolnikov v skupini, ki je prejemala placebo.
After having been treated for an acute episode for 6 weeks and stabilised for an additional 8 weeks with INVEGA (doses ranging from 3 to 15 mg once daily) patients were then randomised in a double-blind manner to either continue on INVEGA or on placebo until they experienced a relapse in schizophrenia symptoms.
Po 6-tedenskem zdravljenju akutne epizode z zdravilom INVEGA (odmerki so bili v razponu od 3 do 15 mg enkrat na dan) in stabilizaciji stanja v dodatnih 8 tednih so bolnike randomizirali na dvojno slep način v dve skupini: ena je nadaljevala zdravljenje z zdravilom INVEGA, druga pa je jemala placebo, dokler se niso ponovili simptomi shizofrenije.
Paliperidone is not expected to cause clinically important pharmacokinetic interactions with medicines that are metabolised by cytochrome P-450 isozymes.
Možnost, da bo zdravilo INVEGA vplivalo na druga zdravila Ni pričakovati, da bi paliperidon povzročil klinično pomembne farmakokinetične interakcije z zdravili, ki se presnavljajo z izoencimi citokroma P-450.
Infections and infestations bronchitis, upper respiratory tract infection, sinusitis, urinary tract infection, influenza pneumonia, respiratory tract infection, cystitis, ear infection, tonsillitis eye infection, onychomycosis, cellulitis, acarodermatitis
Infekcijske in parazitske bolezni bronhitis, okužba zgornjih dihal, sinuzitis, okužba sečil, gripa pljučnica, okužba dihal, cistitis, okužba ušesa, tonzilitis okužba očesa, onihomikoza, celulitis, akarodermatitis
• chest pain, chest discomfort, feeling unwell
• bolečina v prsih, nelagodje v prsih, slabo počutje
Antipsychotic medicinal products (including risperidone) with α-adrenergic blocking effects have been reported to induce priapism.
Poročali so, da antipsihotiki z zaviralnim delovanjem na adrenergične receptorje alfa (vključno z risperidonom) povzročajo priapizem.
INVEGA is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.
Zdravilo INVEGA je indicirano za zdravljenje shizofrenije pri odraslih in mladostnikih, starih 15 let in več.
Abnormalities of electrical function in the heart may occur when this medicine is taken with certain heart medicines that control heart rhythm, or some other types of medicines such as antihistamines, antimalarials, or other antipsychotics.
Če to zdravilo jemljete z določenimi zdravili za srce, ki nadzorujejo srčni ritem ali z nekaterimi zdravili kot so antihistaminiki, antimalariki ali z drugimi antipsihotiki, se lahko pojavijo nepravilnosti v električni funkciji srca.
• thickening of the skin, dry skin, skin redness, skin discolouration, flaky itchy scalp or skin,
• stanjšanje kože, suha koža, rdečica kože, razbarvanje kože, luskasta, srbeča koža skalpa, prhljaj
For adolescents weighing less than 51 kg the dose may be increased to 6 mg once a day.
Pri mladostnikih s telesno maso manjšo od 51 kg in več se odmerek zdravila lahko poveča na 6 mg enkrat na dan.
What INVEGA looks like and contents of the pack INVEGA prolonged-release tablets are capsule shaped.
INVEGA tablete s podaljšanim sproščanjem so v obliki kapsule.
Take this medicine exactly as the doctor, pharmacist or nurse has told you to.
Pri jemanju tega zdravila natančno upoštevajte navodila zdravnika, farmacevta ali medicinske sestre.
CARTON FOR PVC-PCTFE/ALUMINIUM BLISTER (for white and clear blister)
ŠKATLA ZA PRETISNE OMOTE IZ PVC-PCTFE/ALU (za bele in prozorne pretisne omote)
• breast swelling in boys
• otekanje prsi pri fantih
7 TABLET OPA-ALU-PVC/ALU BLISTER
PRETISNI OMOTI IZ OPA-ALU-PVC/ALU S 7 TABLETAMI
The safety and efficacy of INVEGA in the treatment of schizophrenia in adolescents between 12 and 14 years old has not been established.
Varnost in učinkovitost zdravila INVEGA pri zdravljenju shizofrenije pri mladostnikih, starih med 12 in 14 let nista bili dokazani.
When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of 5 days or more.
Kadar je indicirano povečanje odmerka, je priporočeno povečevanje po 3 mg na dan, v intervalih po 5 dni ali več.
In vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, but there are no indications in vitro nor in vivo that these isozymes play a significant role in the metabolism of paliperidone.
Možnost, da bodo druga zdravila vplivala na zdravilo INVEGA In vitro študije kažejo, da izoencima CYP2D6 in CYP3A4 lahko minimalno sodelujeta v presnovi paliperidona, vendar ni nikakršnih znakov in vitro ali in vivo, da bi imela ta dva izoencima pomembno vlogo pri presnovi paliperidona.
• pneumonia, infection of the breathing passages, bladder infection, ear infection, tonsillitis
• pljučnica, okužba dihalnih poti, okužba sečnega mehurja, okužba v ušesu, tonzilitis (vnetje mandljev)
Polyethylene glycol 400 (6, 9 and 12 mg tablet only) Ferric Oxide (Yellow) (E172) (6, 12 mg tablet only) Ferric Oxide (Red) (E172) ( 6, 9 mg tablet only) Lactose monohydrate (3 mg tablet only) Triacetin (3 mg tablet only) Carnauba wax
Obloga: hipromeloza titanov dioksid (E171) makrogol 400 (samo v 6 mg, 9 mg in 12 mg tabletah) rumeni železov oksid (E172) (samo v 6 mg in 12 mg tabletah) rdeči železov oksid (E172) (samo v 6 mg in 9 mg tabletah) laktoza monohidrat (samo v 3 mg tabletah) triacetin (samo v 3 mg tabletah) karnauba vosek
- if you have liver problems.
- Če imate težave z delovanjem ledvic.
pollakiuria, urinary retention, dysuria
Bolezni sečil inkontinenca urina, polakiurija, retenca urina, disurija
Nervous system disorders parkinsonism , akathisia b,
Bolezni živčevja parkinsonizem b,
Blisters: Do not store above 30°C.
Shranjujte pri temperaturi do 30 C.
Torsade de pointes and ventricular fibrillation have been reported in association with overdose.
Pri prevelikem odmerjanju so poročali o torsade de pointes in fibrilaciji ventriklov.
• sore throat, cough, stuffy nose
• vneto grlo, kašelj, zamašen nos
For adolescents weighing 51 kg or more the dose may be increased within the range of 6 mg to 12 mg once a day.
Pri mladostnikih s telesno maso 51 kg in več se odmerek zdravila lahko poveča od 6 mg do 12 mg enkrat na dan.
In schizophrenia clinical trials, the proportions of subjects meeting a weight gain criterion of ≥ 7% of body weight were compared, revealing a similar incidence of weight gain for INVEGA 3 mg and 6 mg compared with placebo, and a higher incidence of weight gain for INVEGA 9 mg and 12 mg compared with placebo.
Primerjava je pokazala podobno incidenco povečanja telesne mase pri zdravilu INVEGA 3 mg in 6 mg kot pri placebu in večjo incidenco povečanja telesne mase pri zdravilu INVEGA 9 mg in 12 mg v primerjavi s placebom.